TransBiotec, Inc. (IMLE) financial statements (2021 and earlier)

Company profile

Business Address 885 ARAPAHOE ROAD
BOULDER, CO 80302
State of Incorp. DE
Fiscal Year End December 31
SIC 2721 - Periodicals: Publishing, or Publishing and Printing (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments010000
Cash and cash equivalents010000
Receivables (1)11  
Prepaid expense0000  
Other undisclosed current assets 1(1)(1)  
Total current assets:010000
Noncurrent Assets
Intangible assets, net (including goodwill)4     
Intangible assets, net (excluding goodwill)4     
Other noncurrent assets0     
Total noncurrent assets:4     
TOTAL ASSETS:410000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities111111
Accounts payable000001
Accrued liabilities000   
Interest and dividends payable011000
Debt000000
Derivative instruments and hedges, liabilities 0    
Due to related parties012221
Other undisclosed current liabilities020000
Total current liabilities:143332
Noncurrent Liabilities
Total liabilities:143332
Stockholders' equity
Stockholders' equity attributable to parent, including:3(4)(3)(3)(3)(2)
Common stock000000
Common stock, value, subscriptions00    
Additional paid in capital531615151414
Accumulated deficit(50)(20)(18)(18)(17)(16)
Other undisclosed stockholders' equity attributable to parent(0)(0)(0)(0)(0)(0)
Stockholders' equity attributable to noncontrolling interest(0)(0)(0)   
Other undisclosed stockholders' equity000000
Total stockholders' equity:3(4)(3)(3)(3)(2)
Other undisclosed liabilities and equity (0)(0)(0)(0)(0)
TOTAL LIABILITIES AND EQUITY:410000

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Gross profit: 0    
Operating expenses(3)(1)(0)(0)(0)(0)
Other undisclosed operating loss (0)    
Operating loss:(3)(1)(0)(0)(0)(0)
Nonoperating expense (0)(0)(0)(0)(0)
Interest and debt expense00(0) 00
Loss from continuing operations before equity method investments, income taxes:(3)(1)(1)(1)(1)(1)
Other undisclosed income (loss) from continuing operations before income taxes  0 (0)(0)
Loss from continuing operations before income taxes:(3)(1)(1)(1)(1)(1)
Income tax expense  (1)   
Loss before gain (loss) on sale of properties:(3)(1)(1)(1)(1)(1)
Other undisclosed net loss (0)    
Net loss:(3)(1)(1)(1)(1)(1)
Net income attributable to noncontrolling interest   000
Other undisclosed net income (loss) attributable to parent(27) 1   
Net loss attributable to parent:(30)(1)(1)(1)(1)(1)
Preferred stock dividends and other adjustments0     
Net loss available to common stockholders, diluted:(30)(1)(1)(1)(1)(1)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(3)(1)(1)(1)(1)(1)
Other undisclosed comprehensive income3     
Comprehensive income (loss):0(1)(1)(1)(1)(1)
Comprehensive income, net of tax, attributable to noncontrolling interest   000
Comprehensive income (loss), net of tax, attributable to parent:0(1)(1)(1)(1)(1)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: